ClinicalTrials.gg
CompletedNCT04787302Updated Jul 27, 2023

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

A Phase 1 interventional study of CVL-231 and CVL-231 in Schizophrenia, sponsored by Cerevel Therapeutics, LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
27th of 27
15 · median 268
Started
2021
with 2 others
Phase 1
6 of 27
none open now
Registered
20th of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 27th largest by enrollment, is one of 3 that started in 2021, is one of 6 in phase 1, and was the 20th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing

Read the detailed description

CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR). CVL-231 is being developed for treatment of psychosis in schizophrenia. The aim of this trial is to characterize the relationship between the M4 receptor occupancy in different regions of the brain following a single oral doses of CVL-231 in healthy adult subjects by positron emission tomography (PET) using the radioligand [11C]MK-6884.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • PET
  • Healthy Volunteer
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 55 years, inclusive, at the time of signing the ICF
  • Sexually active men with a pregnant or a nonpregnant partner of must agree to use a double-barrier method of , including a condom, and practice contraception during treatment and through 7 days post dose
  • Capable of providing and following study requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects who answer yes on the C-SSRS or, in the opinion of the investigator, present a serious risk of suicide
  • Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease
  • Subjects with a 12-lead demonstrating either of the following (average of 3 ECGs obtained at the Screening Visit):

    • corrected for heart rate using Fridericia's formula >450 msec
    • Left ventricular hypertrophy
  • Orthostatic hypotension, which is defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the immediately previous supine/semi-recumbent blood pressure at Screening or at the prescan time point prior to baseline PET scan.
  • Subjects with a current or past personal history of any psychiatric disorder as classified by criteria or immediate family members with any psychiatric disorder as classified by DSM-5 criteria that require treatment
  • Subjects with a history of substance or alcohol-use disorder (DSM-5 criteria) within 2 years prior to signing the ICF
  • Subjects with other abnormal laboratory test results, vital sign results, or ECG findings
  • Subjects who currently use or have used tobacco or nicotine-containing products within 30 days prior to signing the ICF
  • Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure (5 rem per year)
  • Subjects with any anatomical abnormality in the head that would either preclude or tend to confound the analysis of study data, including any abnormal findings from MRI of the head
  • Current, past or anticipated exposure to radiation in the workplace
  • Any subject with a significant acute illness within 7 days prior to administration of study drug or have had a major illness or hospitalization within 1 month prior to administration of study drug
  • Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    CVL-231

    Drug: CVL-231

Interventions

  • Cohort 1: 30mg dose of CVL-231

    Also known as: PF-06852231

  • Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded

    Also known as: PF-06852231

  • Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2

    Also known as: PF-06852231

06

What researchers measure

Primary outcomes

  1. M4 receptor occupancy in the striatum following single oral doses of CVL-231 in healthy adult subjects

    Fraction of M4 receptors occupied by CVL-231 doses

    Time frame: Day 1

Secondary outcomes

  1. Treatment-emergent adverse events

    Time frame: Upto 9 weeks

  2. Number of subjects with Clinically significant changes in Electrocardiogram

    Time frame: Screening, Pre-scan, Day-1, Day 1 (T=0hour), Day 1 (T=0.5hour), Day 1 (T=3.0hour), Day 2 (T=24hour), Day 10

  3. Number of subjects with clinical significant Clinical laboratory assessments

    Time frame: Screening, Pre-scan, Day-1, Day 2 (T=24hour)

  4. Number of subjects with Clinically significant changes in Vital signs

    Time frame: Screening, Day-1 (T=1hour), Day-1 (T=1.5hour), Day-1, Day 1 (T=0hour), Day 1(T=1.5hour), Day 1 (T=3hour), Day 1 (T=6hr), Day 1 (T=8.0), Day 2 (T-=24hr), Day 10

  5. Number of subjects with clinically significant Physical and neurological examination results

    Time frame: Screening, Day-1 pre-scan, Day-1, Day 2

  6. Suicidality assessed using the Columbia-Suicide Severity Rating Scale

    Suicidality will be monitored during the trial using the Columbia - Suicide Severity Rating Scale (C-SSRS)

    Time frame: Screening, Day-1, Day 2, Day 10

  7. Cmax during scan for CVL-231

    Max CVL-231 concentration during PET scan

    Time frame: Day 1 (0.5, 1.5 and 2.0 hours)

  8. AUCscan duration for CVL-231

    AUC for CVL-231 during PET scan

    Time frame: Day 1 (0.5, 1.5 and 2.0 hours)

  9. Cavg/Scan duration for CVL-231

    Average CVL-231 concentration during scan

    Time frame: Day 1 (0.5, 1.5 and 2.0 hours)

  10. Model estimated Emax and EC50 at M4 receptors in striatum for CVL-231

    Model estimated values for Maximum possible binding (Emax) and CVL-231 concentrations required from hal-maximal binding (EC50)

    Time frame: Day 1

07

Study locations

2 sites
  • Massachusetts General Hospital Translational and Clinical Research Centers
    Boston, Massachusetts 02114, United States
  • UZ Leuven
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2023, 25 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 25 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Mar 8, 2021
StartActual
Jun 1, 2021
Primary completionActual
Jul 14, 2023
CompletionActual
Jul 14, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04787302
Responsible party
Sponsor
First posted
Mar 8, 2021
Start date
Jun 1, 2021
Primary completion
Jul 14, 2023
Completion
Jul 14, 2023
Last update
Jul 27, 2023

Study contacts

Matthew Leoni, MD, MBA
study director · Cerevel Therapeutics, LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion